{"id":3376,"date":"2020-01-01T09:54:28","date_gmt":"2020-01-01T09:54:28","guid":{"rendered":"http:\/\/www.citiusminds.com\/blog\/?p=3376"},"modified":"2021-07-24T13:58:14","modified_gmt":"2021-07-24T18:58:14","slug":"a-novel-step-towards-universal-influenza-vaccine","status":"publish","type":"post","link":"https:\/\/www.citiusminds.com\/blog\/a-novel-step-towards-universal-influenza-vaccine\/","title":{"rendered":"A Novel step towards Universal Influenza Vaccine"},"content":{"rendered":"\n<p>Influenza is a significant cause of death caused by the influenza virus affecting the respiratory tract by infection. Different strains of the virus cause it. Type A and Type B are the most common strains affecting humans, birds, and pigs. Therefore, universal influenza vaccination is needed to cut the outbreak of this respiratory illness each season. Since seasoned flu vaccinations are insufficient to eliminate the threats of influenza disease, a novel nanoparticle vaccination has been developed by researchers at Georgia State University (GSU) to provide universal protection against all virulent strains of the influenza virus, eliminating the need for vaccinations in each season.<\/p>\n\n\n\n<p>Researchers utilized two influenza proteins to develop nanoparticle vaccination in mice. It comprises a combination of two proteins that are majorly found in all strains of influenza virus (i.e., matrix protein 2 ectodomain (M2e) and neuraminidase (NA), specifically NA found on the surface of the virus. According to a study by the Institute for Biomedical Sciences at Georgia State University, the findings of the research have been published in the journal Advanced Healthcare Materials.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.citiusminds.com\/blog\/wp-content\/uploads\/2020\/01\/diana-polekhina-ZBstHWt9vLc-unsplash-scaled.jpg\"><img decoding=\"async\" src=\"https:\/\/www.citiusminds.com\/blog\/wp-content\/uploads\/2020\/01\/diana-polekhina-ZBstHWt9vLc-unsplash-1024x637.jpg\" alt=\"\" class=\"wp-image-3789\"\/><\/a><\/figure>\n\n\n\n<p>Ye Wang was the first author of the study. He is a biology Ph.D. student working in Dr. Bao-Zhong Wang&#8217;s lab at the Institute for Biomedical Sciences. Wang said, &#8220;This nanoparticle antigen combination conferred mice with strong cross-protection,&#8221; and that &#8220;It can protect mice from different strains of influenza virus. Each season, we have different flu strains that affect us. So by using this approach, we hope this nanoparticle vaccine can protect humans from different strains of influenza virus.&#8221;<\/p>\n\n\n\n<p>This\ndouble-layered nanoparticle vaccination containing M2e (matrix\nprotein 2 ectodomain) as the core, and NA (neuraminidase)\nis coated on the surface. According to the study, all mice were immunized with\nnanoparticle vaccine intramuscularly and then exposed to one of six influenza\nvirus strains of the influenza virus. And all mice developed immunity or\nprotection against six different types of Influenza strains.<\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"690\" height=\"686\" src=\"https:\/\/www.citiusminds.com\/blog\/wp-content\/uploads\/2020\/01\/flu2.jpg\" alt=\"\" class=\"wp-image-3378\" srcset=\"https:\/\/www.citiusminds.com\/blog\/wp-content\/uploads\/2020\/01\/flu2.jpg 690w, https:\/\/www.citiusminds.com\/blog\/wp-content\/uploads\/2020\/01\/flu2-300x298.jpg 300w, https:\/\/www.citiusminds.com\/blog\/wp-content\/uploads\/2020\/01\/flu2-150x150.jpg 150w, https:\/\/www.citiusminds.com\/blog\/wp-content\/uploads\/2020\/01\/flu2-640x636.jpg 640w\" sizes=\"(max-width: 690px) 100vw, 690px\" \/><figcaption> Ye Wang, first author of the study and a biology Ph.D. student working in Dr. Bao-Zhong Wang&#8217;s lab in the Institute for Biomedical Sciences at Georgia State University  (<a href=\"https:\/\/www.eurekalert.org\/multimedia\/pub\/220894.php\">Source<\/a>) <\/figcaption><\/figure><\/div>\n\n\n\n<p>&#8220;It&#8217;s important to mention that a lot of flu vaccines haven&#8217;t focused on NA before,&#8221; said Gilbert Gonzalez, co-author of the study and lab manager in Dr. Bao-Zhong Wang&#8217;s lab in the Institute for Biomedical Sciences. &#8220;NA is becoming a more important antigen for influenza vaccine research. Previously, it had been ignored or discounted because hemagglutinin (HA) is much more dominant. When you get a flu infection, your body reacts to the HA.&#8221;<\/p>\n\n\n\n<p>The vaccine has proved\nto be a promising universal long-lasting immune-protection for up to four\nmonths after immunizations. Next, researchers are planning to load the\nnanoparticle vaccine onto microneedle patches for skin vaccination.<strong><\/strong>\n\nThe Patent Application No. <a href=\"https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2019070955\">WO2019070955A1<\/a>, filed\nby Georgia State Univ Research Foundation Inc (US), discloses the vaccine\ncompositions and methods based on a truncated influenza HA protein lacking a\nhead domain. Also disclosed is a nanoparticle formed by desolvating the fusion\nprotein with a desolvating agent and\/or crosslinking a fusion protein with a\ncrosslinking agent, wherein the fusion protein comprises a series of 2 to 8\ninfluenza virus matrix protein 2 extracellular (M2e) domains linked to a\nmultimerization domain, wherein the fusion protein further comprises influenza\nneuraminidase (NA) protein linked to the multimerization domain. This\nnanoparticle can, in some embodiments, be coated with an antigen, such as the\ndisclosed hrHA (Influenza hemagglutinin (HA) protein lacking a head domain) polypeptide.\n\n\n\n<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Influenza is a significant cause of death caused by the influenza virus affecting the respiratory tract by infection. Different strains of the virus cause it. Type A and Type B are the most common strains affecting humans, birds, and pigs. Therefore, universal influenza vaccination is needed to cut the outbreak of this respiratory illness each [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3784,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[30,44],"class_list":["post-3376","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-from-the-greatest","tag-patent","tag-patent-application"],"_links":{"self":[{"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/posts\/3376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/comments?post=3376"}],"version-history":[{"count":0,"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/posts\/3376\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/media\/3784"}],"wp:attachment":[{"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/media?parent=3376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/categories?post=3376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.citiusminds.com\/blog\/wp-json\/wp\/v2\/tags?post=3376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}